RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Financials
  4. Revenue growth (%)

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 2024-3.8-95.36%
Dec 31, 2023-82.3+104.68%
Dec 31, 2022-40.2-122.06%
Dec 31, 2021182.2-338.28%
Dec 31, 2020-76.5+63.38%
Dec 31, 2019-46.8-142.74%
Dec 31, 2018109.5+448.55%
Dec 31, 201720-36.59%
Dec 31, 201631.5-176.32%
Dec 31, 2015-41.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)